Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Innovent Biologics ( (HK:1801) ) just unveiled an update.
Innovent Biologics has announced that China’s National Medical Products Administration has accepted the supplementary application for the 9mg dosage of mazdutide, a dual receptor agonist for weight management in adults with moderate to severe obesity. The acceptance is based on successful Phase 3 clinical trial results, demonstrating significant weight loss and improved cardiometabolic health markers. This development positions Innovent to offer a novel, effective treatment alternative to surgery for obesity in China, potentially impacting the company’s market presence and providing a personalized medical solution for patients.
The most recent analyst rating on (HK:1801) stock is a Hold with a HK$89.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines, particularly in the field of biologics. The company has a strategic partnership with Eli Lilly and Company for the development of mazdutide, a dual GCG/GLP-1 receptor agonist, aimed at addressing obesity and related metabolic disorders in China.
Average Trading Volume: 18,034,933
Technical Sentiment Signal: Buy
Current Market Cap: HK$157.7B
See more data about 1801 stock on TipRanks’ Stock Analysis page.